5-Fluorouracil Toxicity — DPYD variants that turn standard chemotherapy doses into life-threatening overdoses, now mandated for pre-treatment screening by the European Medicines Agency.
Whole genome sequencing identifies all DPYD variants — including the rare alleles beyond the standard four-variant panel — providing the complete genotype needed to prevent fluoropyrimidine toxicity before the first chemotherapy infusion.
5-Fluorouracil Toxicity — DPYD
5-Fluorouracil (5-FU) and its oral prodrug capecitabine are among the most widely prescribed chemotherapy agents worldwide, forming the backbone of treatment regimens for colorectal, gastric, pancreatic, breast, and head and neck cancers. More than 2 million patients receive fluoropyrimidine-based chemotherapy annually. Dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene, is responsible for the rate-limiting step in fluoropyrimidine catabolism — it degrades over 80% of administered 5-FU. Patients with partial or complete DPD deficiency cannot clear 5-FU at normal rates, resulting in prolonged exposure to cytotoxic drug levels.
DPYD deficiency causes severe and potentially fatal fluoropyrimidine toxicity including grade 3-4 neutropenia, severe mucositis, hand-foot syndrome, diarrhea, and in the most severe cases, sepsis, multi-organ failure, and death. Approximately 3-8% of the general population carries at least one DPYD variant associated with reduced DPD activity. Complete DPD deficiency (homozygous or compound heterozygous for loss-of-function variants) is rare (~0.1%) but carries a mortality rate exceeding 10% with standard-dose fluoropyrimidine treatment. Four DPYD variants account for the majority of clinically significant DPD deficiency: DPYD*2A (c.1905+1G>A, IVS14+1G>A), c.2846A>T (p.Asp949Val), c.1679T>G (DPYD*13, p.Ile560Ser), and c.1236G>A/HapB3.
The European Medicines Agency (EMA) mandated pre-treatment DPYD genotyping for all patients receiving fluoropyrimidine chemotherapy effective 2020, recommending at minimum testing for the four variants above with dose reduction of 25-50% for heterozygous carriers and avoidance of fluoropyrimidines for complete DPD deficiency. CPIC and DPWG guidelines (Level A) provide detailed genotype-to-phenotype translation and dosing recommendations. Despite the clinical evidence and regulatory mandates, implementation of pre-treatment DPYD testing remains inconsistent — particularly in the United States, where it is recommended but not universally required.
Over 30 DPYD variants with reduced function have been documented. The standard four-variant DPYD panel captures approximately 50-80% of clinically significant DPD deficiency; the remaining cases carry rare variants detectable only by complete gene sequencing.
Standard DPYD panels test four variants that explain only 50-80% of clinically significant DPD deficiency. Rare DPYD variants that cause severe toxicity exist in every population and require complete gene sequencing to detect.
The standard four-variant panel misses a substantial fraction of DPD-deficient patients
Multiple studies have documented patients who experienced severe fluoropyrimidine toxicity despite testing negative on standard four-variant DPYD panels. A Dutch study of fluoropyrimidine-related deaths found that approximately 30-50% of patients with lethal toxicity were negative for the four standard variants — they carried rare DPYD variants not included on the standard panel. Over 30 DPYD coding variants with reduced or absent enzyme activity have been characterized; many are population-specific and present at frequencies too low for inclusion on fixed-content panels but high enough to account for a meaningful fraction of severe toxicity events at the population level. Complete DPYD sequencing by whole genome analysis captures all of these.
The DPYD result is needed before the first chemotherapy dose — not after toxicity occurs
Fluoropyrimidine toxicity in DPD-deficient patients typically manifests during the first cycle of treatment. Once severe toxicity has occurred, the clinical damage — neutropenic sepsis, severe mucositis, toxic death — cannot be reversed by dose reduction in subsequent cycles. Pre-treatment DPYD genotyping enables prospective dose adjustment before any drug exposure occurs. For carriers of the four standard variants, CPIC recommends 25-50% dose reduction with subsequent dose titration based on tolerability; for patients with complete DPD deficiency, fluoropyrimidines are contraindicated entirely and alternative agents must be selected. Having the complete DPYD genotype in the medical record before oncology treatment planning begins enables these critical decisions.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for 5-Fluorouracil Toxicity — DPYD and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
